Immune Design Corp. (NASDAQ:IMDZ)’s share price traded up 5.5% during trading on Wednesday . The stock traded as high as $7.84 and last traded at $7.81, with a volume of 50,520 shares changing hands. The stock had previously closed at $7.40.

Several equities analysts have recently commented on the company. Jefferies Group reiterated a “buy” rating and set a $20.00 price objective on shares of Immune Design Corp. in a research report on Sunday, May 29th. Cowen and Company reiterated an “outperform” rating on shares of Immune Design Corp. in a research report on Wednesday, April 27th. Leerink Swann reiterated a “buy” rating on shares of Immune Design Corp. in a research report on Thursday, May 12th. Zacks Investment Research lowered Immune Design Corp. from a “hold” rating to a “sell” rating in a research report on Tuesday, July 12th. Finally, Wells Fargo & Co. restated a “buy” rating on shares of Immune Design Corp. in a research report on Wednesday, May 11th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $24.00.

The company’s market cap is $157.39 million. The stock has a 50-day moving average of $7.99 and a 200-day moving average of $11.10.

Immune Design Corp. (NASDAQ:IMDZ) last released its quarterly earnings results on Tuesday, May 10th. The company reported ($0.61) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.62) by $0.01. Equities research analysts predict that Immune Design Corp. will post ($2.70) earnings per share for the current year.

Other institutional investors have made changes to their positions in the company. Jennison Associates increased its position in shares of Immune Design Corp. by 0.6% in the third quarter. Jennison Associates now owns 202,683 shares of the company’s stock valued at $2,473,000 after buying an additional 1,224 shares during the last quarter. Jennison Associates LLC increased its position in shares of Immune Design Corp. by 0.4% in the fourth quarter. Jennison Associates LLC now owns 203,452 shares of the company’s stock valued at $4,085,000 after buying an additional 769 shares during the last quarter. Finally, RS Investment Management Co. LLC increased its position in shares of Immune Design Corp. by 12.5% in the fourth quarter. RS Investment Management Co. LLC now owns 1,108,576 shares of the company’s stock valued at $22,260,000 after buying an additional 122,910 shares during the last quarter.

Immune Design Corp. is a clinical stage immunotherapy company. The Company focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.